Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can friendly gut bacteria beat superbugs? new study explores natural decolonization

NCT ID NCT04764500

Knowledge-focused Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 39 travelers to Southeast Asia to see if their guts naturally clear a type of antibiotic-resistant E. coli (ESBL E. coli) over time. Participants provided stool samples before and after travel and up to a year later. The goal was to understand how the body's own microbes might help push out resistant bacteria.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could point toward using harmless E. coli to help clear resistant bacteria from the gut naturally.
What could go wrong
This is a small observational study, not a treatment trial. It only looks at natural decolonization, so it may not lead to a therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

39 people

The number who actually took part.

Started

Jun 2019

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Clients planning to travel to Southeast Asia will be recruited while receiving pre-travel health advice at the travel clinic of the Swiss Tropical and Public Health Institute in Basel.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * travelling to Southeast Asia (India, Bhutan, Nepal, Bangladesh, Myanmar, Thailand, Laos, Cambodia, Vietnam) for a maximum of 4 weeks. Exclusion Criteria: * other travelling destinations than mentioned above * antibiotic use at the first sampling time * Participants who are not colonized will serve as a control group for microbiome comparison

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Extended spectrum beta lactamases (ESBL) E. coli are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

escherichia coli infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Extended spectrum beta lactamases (ESBL) E. coli

Contacts and locations

Locations

  • University Hospital Basel, Division of Clinical Microbiology

    Basel, 4031, Switzerland